Andrew Frank
MD, BScH, FRCPC
Investigator
Cognitive Neurologist
Bruyère Memory Program
Assistant Professor
University of Ottawa
About:
Dr. Andrew Frank is a cognitive/behavioural neurologist and researcher at Bruyère Memory Program at the Bruyère Health Élisabeth-Bruyère Hospital in Ottawa, Ontario.
After finishing his Bachelor’s degree in Honours Biochemistry at the University of Calgary, Dr. Frank completed his M.D. at the University of British Columbia in Vancouver. He completed his residency in Neurology at the University of Ottawa. Following this, Dr. Frank undertook a subspecialty fellowship in Cognitive and Behavioural Neurology at the Mayo Clinic in Rochester, Minnesota.
Dr. Frank’s clinical practice is focused on the diagnosis and treatment of neurodegenerative diseases, such as dementia due to Alzheimer’s disease. His clinical interest lies in the early detection of cognitive disorders, such as Mild Cognitive Impairment (MCI). Dr. Frank’s research interest centers on investigating new pharmacologic treatments and technologies for Alzheimer’s disease.
Research Interests:
Alzheimer's Disease, dementia, mild cognitive impairment, therapeutics, technology.
Select Publications:
Frank A, Ismail Z, Wilson M, Gauthier S, Verret L, Hsiung GR, Borrie M. (2023). Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion. Canadian Journal of Neurological Sciences.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators (includes Frank A). (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA.
Sheehy L, Bouchard S, Kakkar A, El Hakim R, Lhoest J, Frank A. (2024). Development and Initial Testing of an Artificial Intelligence-Based Virtual Reality Companion for People Living with Dementia in Long-Term Care. Journal of Clinical Medicine.
Sanchez E, Wilkinson T, Coughlan G, Mirza S, Baril AA, Ramirez J, Binns MA, Black SE, Borrie M, Dilliott AA, Dixon RA, Dowlatshahi D, Farhan S, Finger E, Fischer CE, Frank A, Freedman M, Goncalves RA, Grimes DA, Hassan A, Hegele RA, Kumar S, Lang AE, Marras C, McLaughlin PM, Orange JB, Pasternak SH, Pollock BG, Rajji TK, Roberts AC, Robinson JF, Rogaeva E, Sahlas DJ, Saposnik G, Strong MJ, Swartz RH, Tang-Wai DF, Tartaglia MC, Troyer AK, Kvartsberg H, Zetterberg H, Munoz DP; ONDRI Investigators; Masellis M. (2023). Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimer's & Dementia.
Contact:
afrank@bruyere.org